Linker Information
General Information of This Linker
| Linker ID |
LIN0MFHKQ
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Alkyl phosphoramide-PEG24-Val-Cit-PAB
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C75H131N6O31P
|
|||||
| Isosmiles |
C#CP(=O)(Nc1ccc(C(=O)NC(C(=O)NC(CCCNC(N)=O)C(=O)Nc2ccc(CO)cc2)C(C)C)cc1)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
|
|||||
| InChI |
InChI=1S/C75H131N6O31P/c1-4-113(88,81-69-13-9-67(10-14-69)72(84)80-71(65(2)3)74(86)79-70(6-5-15-77-75(76)87)73(85)78-68-11-7-66(64-83)8-12-68)112-63-62-111-61-60-110-59-58-109-57-56-108-55-54-107-53-52-106-51-50-105-49-48-104-47-46-103-45-44-102-43-42-101-41-40-100-39-38-99-37-36-98-35-34-97-33-32-96-31-30-95-29-28-94-27-26-93-25-24-92-23-22-91-21-20-90-19-18-89-17-16-82/h1,7-14,65,70-71,82-83H,5-6,15-64H2,2-3H3,(H,78,85)(H,79,86)(H,80,84)(H,81,88)(H3,76,77,87)
|
|||||
| InChIKey |
PLVBDTJIUHDXIM-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1643.858
|
Polar area
|
433.5
|
||
|
Complexity
|
113
|
xlogp Value
|
2.0917
|
|||
|
Heavy Count
|
113
|
Rot Bonds
|
86
|
|||
|
Hbond acc
|
31
|
Hbond Donor
|
8
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Brentuximab-8 [Clinical candidate]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.60 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.50 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Hodgkin lymphoma | L-540 cells | CVCL_1362 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
4.20 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.10 pM
|
High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.